EMAP (Extensive Macular Atrophy with Pseudodrusen) is a maculopathy we recently described that shares pseudodrusen and geographic atrophy with Age-related Macular Disease (AMD). EMAP differs from AMD by an earlier age of onset (50-55 years) and a characteristic natural history comprising a night blindness followed by a severe visual loss. In a prospective case-control study, ten referral centers included 115 EMAP (70 women, 45 men) patients and 345 matched controls to appraise dietary, environmental, and genetic risk factors. The incidence of EMAP (mean 2.95/1.10) was lower in Provence-Côte d'Azur with a Mediterranean diet (1.9/1.10), and higher in regions with intensive farming or industrialized activities (5 to 20/1.10). EMAP patients reported toxic exposure during professional activities (OR 2.29). The frequencies of common AMD complement factor risk alleles were comparable in EMAP. By contrast, only one EMAP patient had a rare AMD variant. This study suggests that EMAP could be a neurodegenerative disorder caused by lifelong toxic exposure and that it is associated with a chronic inflammation and abnormal complement pathway regulation. This leads to diffuse subretinal deposits with rod dysfunction and cone apoptosis around the age of 50 with characteristic extensive macular atrophy and paving stones in the far peripheral retina.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931512 | PMC |
http://dx.doi.org/10.1038/s41598-018-25003-9 | DOI Listing |
Cureus
December 2024
Department of Ophthalmology, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, SAU.
We report the presentation and outcome of Terson syndrome in four eyes of two infants in a tertiary hospital in Saudi Arabia. This is a retrospective report of two infants with Terson syndrome due to accidental traumatic head injuries. Intraoperative screenshots of the posterior pole were taken for both cases.
View Article and Find Full Text PDFOphthalmol Sci
October 2024
Genentech, Inc., South San Francisco, California.
Purpose: The region of growth (ROG) of geographic atrophy (GA) throughout the macular area has an impact on visual outcomes. Here, we developed multiple deep learning models to predict the 1-year ROG of GA lesions using fundus autofluorescence (FAF) images.
Design: In this retrospective analysis, 3 types of models were developed using FAF images collected 6 months after baseline to predict the GA lesion area (segmented lesion mask) at 1.
Am J Ophthalmol
December 2024
Department of Ophthalmology, New Civil Hospital, Strasbourg University Hospital, FMTS, Strasbourg, France. Electronic address:
Purpose: To describe a new feature in pathologic myopia: perivascular patchy chorioretinal atrophy (PVCA) DESIGN: Cross-sectional study METHODS: 604 eyes of 312 highly myopic patients followed at Strasbourg University Hospitals were reviewed for the presence of PVCA lesions. Demographic, clinical, and paraclinical data (ultra-widefield retinography, optical coherence tomography (OCT), fluorescein and indocyanine green angiography images) were analyzed. Controls were matched for age, sex, and axial length (AL).
View Article and Find Full Text PDFJ Manag Care Spec Pharm
January 2025
Humana Healthcare Research, Inc., Louisville, KY.
Background: Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration (AMD) that can lead to visual impairment. Published studies estimate approximately 1 million people in the United States have GA in at least 1 eye. There is a lack of real-world evidence from the US payer perspective on the prevalence of AMD and GA among Medicare Advantage prescription drug (MAPD) plan enrollees.
View Article and Find Full Text PDFJ Manag Care Spec Pharm
January 2025
Humana Healthcare Research, Inc., Louisville, KY.
Background: Geographic atrophy (GA) is a form of advanced age-related macular degeneration (AMD) that can cause irreversible vision impairment and is responsible for approximately 20% of legal blindness in the United States. There is limited real-world evidence assessing health outcomes and health care resource use (HCRU) among individuals with GA.
Objective: To examine the progression from GA without subfoveal involvement (SFI) to GA with SFI, progression to irreversible blindness, and HCRU among older individuals with GA enrolled in Medicare Advantage Prescription Drug (MAPD) plans.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!